HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combined regional and systemic chemotherapy for advanced and inoperable non-small cell lung cancer.

AbstractAIMS:
The objective was to establish the feasibility and toxicity of regional chemotherapy using an isolated thoracic perfusion (ITP) technique plus low dose systemic chemotherapy as induction chemotherapy followed by surgery in advanced non-small cell lung cancer (NSCLC).
METHODS:
twenty-two chemotherapy-naive patients with NSCLC (median age of 57 years, stage III-IV disease with metastases only in the thoracic region, Karnofsky index >60), received two cycles of regional plus systemic chemotherapy with a treatment-free interval of 4 weeks. The cytostatic regimen consisted of 10 mg/m(2) mitomycin, 25 mg/m(2) navelbine and 30 mg/m(2) cisplatin during ITP followed by low-dose systemic chemotherapy with 250 mg/m(2) 5-fluorouracil and 20 mg/m(2) cisplatin given as a continuous infusion on day 1-4. Patients were re-evaluated for response and surgery was carried out if possible.
RESULTS:
All 22 patients could be assessed for toxicity, response and survival. There were 19/22 remissions corresponding to a regression rate of 86.4%; 16/22 patients could be resected. This corresponded to a resectability rate of 72.7% (13 complete resections R0, 1 R1, 2 R2). Side-effects were transient and acceptable with no treatment- or surgery-related deaths. Median survival has not been reached after an observation time of 15 months. The estimated 1-year survival rate was 67.3%.
CONCLUSIONS:
Regional chemotherapy using an ITP application form is highly effective in advanced NSCLC stage III-IV leading to a high rate of resectability with an encouraging survival outcome.
AuthorsH Müller
JournalEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (Eur J Surg Oncol) Vol. 28 Issue 2 Pg. 165-71 (Mar 2002) ISSN: 0748-7983 [Print] England
PMID11884052 (Publication Type: Clinical Trial, Journal Article)
CopyrightCopyright Harcourt Publishers Limited.
Chemical References
  • Mitomycin
  • Vinblastine
  • Cisplatin
  • Vinorelbine
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, mortality, pathology, secondary)
  • Chemotherapy, Cancer, Regional Perfusion
  • Cisplatin (administration & dosage, adverse effects)
  • Combined Modality Therapy
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Lung Neoplasms (drug therapy, mortality, pathology)
  • Male
  • Middle Aged
  • Mitomycin (administration & dosage, adverse effects)
  • Neoplasm Staging
  • Palliative Care (methods)
  • Prognosis
  • Survival Analysis
  • Terminally Ill
  • Treatment Outcome
  • Vinblastine (administration & dosage, adverse effects, analogs & derivatives)
  • Vinorelbine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: